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Background/aim: Due to the importance of early outpatient treatment to prevent hospitalization and disease progression, we examined
the effects of hydroxychloroquine and favipiravir, which were initiated in early period, on the clinical course of COVID-19 outpatients.
Materials and methods: Data of confirmed COVID-19 outpatients over a 4-month period were analyzed retrospectively. Public
Health Management System (HSYS) was used for the case-based follow-up. Patients on antiviral therapy for at least five days, including
hydroxychloroquine and / or favipiravir and patients who were followed-up for 30 days were included in this analysis.
Results: We enrolled 1489 patients in this study. Overall, 775 (52%) patients were male and a mean age of patients was 38.9 ± 11.1
years. Of these patients, 537 of them were received favipiravir, 545 of them were received hydroxychloroquine and 407 of them were
received both favipiravir and hydroxychloroquine. Symptoms improvement on the 14th day of follow-up was 1.8 times higher in the
group of patients receiving hydroxychloroquine compared to patients who received favipiravir (p = 0.003). On the 3rd day of followup, PCR negativity rate was higher in patients who received hydroxychloroquine (p = 0.004). Hospitalization rates were similar in
patients receiving favipiravir and hydroxychloroquine (p = 0.144). However, in the presence of pneumonia at the time of diagnosis, the
hospitalization rate was 6.6 times higher in patients who received favipiravir than those who received hydroxychloroquine.
Conclusion: The subgroups of patients treated with hydroxychloroquine and/or favipiravir did not have similar disease severities in our
study. Therefore, further studies with homogeneous patient groups to be arranged prospectively are needed.
Key words: COVID-19, hydroxychloroquine, favipiravir, outpatients, treatment

1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic
is the biggest health threat to humanity after the 1918
influenza pandemic. Since its first detection in December
2019, COVID-19 has affected nearly 75 million people in
a year, and more than 1.5 million people have died due
to SARS-CoV-2. SARS-CoV-2 virus causes COVID-19
disease and severe acute respiratory syndrome. The disease
is characterized by flu-like symptoms. Some patients are
asymptomatic, pulmonary involvement often develop in
symptomatic patients and progressive disease can be life
threatening1.
There is no specific drug to treat COVID-19. Since the
beginning of the pandemic, many drugs such as favipiravir,
remdesivir, hydroxychloroquine, lopinavir / ritonavir have
been used in the treatment of the disease. Chloroquine is

a classic antimalarial drug and also has anti-inflammatory
and immunomodulatory effects in viral infections.
Hydroxychloroquine is a chloroquine metabolite and is
less toxic. Chloroquine and hydroxychloroquine have
been demonstrated to inhibit SARS-CoV-2 in vitro, but
their clinical efficacy and benefits are not yet known.
Favipiravir is a nucleotide analogue approved in China
and Japan for the treatment of influenza. Favipiravir
prevents the replication of the RNA virus by selectively
inhibiting RNA-dependent RNA polymerase. Since the
RNA-dependent RNA polymerase gene of SARS-CoV-2
is similar to influenza viruses, it has also been proposed
in the treatment of COVID-19 [1]. Hydroxychloroquine
and favipiravir have been used alone or in combination
in the treatment of COVID-19 since the beginning of the
pandemic in Turkey. In this study, we aimed to investigate

World Health Organisation (2020). Novel coronavirus-2019. Website (https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed
15.12.2020]
1
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the effects of hydroxychloroquine and favipiravir on the
clinical course in COVID-19 outpatients receiving early
treatment.
2. Materials and methods
The study was carried out in the hospitals located in
İzmir, Turkey. This observational retrospective study was
approved by the Clinical Research Ethics Committee of
İzmir Katip Çelebi Üniversitesi, Institutional Review Board.
Data were collected from August 1st to November 30th
from all outpatients diagnosed with definitive COVID-19
and receiving treatment. Reverse transcriptase polymerase
chain reaction (RT-PCR) test was applied to all outpatients
meeting the definition of the possible case definition
according to The Republic of Turkey Ministry of Health
COVID-19 guideline2. PCR sampling frequency was a
part of the routine follow-up process. Patients with PCRdocumented SARS-CoV-2 RNA from nasopharyngeal
samples were prescribed hydroxychloroquine (200 mg
twice daily for 5 days) and favipiravir (two 1600 mg
oral loading doses on day 1, followed by 600 mg twice
daily on days 2-5) as early treatment, whether or not
they had symptoms. Serum electrolyte analysis and
electrocardiogram were evaluated before the treatment.
Public Health Management System (Halk Sağlığı
Yönetim Sistemi-HSYS) was used for the case-based
follow-up. Patients who received antiviral treatment for
at least five days and patients who were followed-up for
30 days were included in this analysis. All PCR-positive
COVID-19 outpatients whose data could be accessed
during the study period were included in the study. A
total of 468 PCR-positive outpatients were excluded from
the study due to being under 18 years of age, previous
COVID-19 diagnosis, pregnancy and missing data. PCR
samplings were repeated on the 1st, 3th, and 14th days.
Symptoms were evaluated on the 1st, 3th, 5th, 14th, and
30th days of follow-up. Demographics and laboratory
results on the day of admission were recorded. COVID-19
pneumonia was confirmed by thoracic computed
tomography (CT). The clinical data (symptoms, antiviralrelated side effects, requirement for hospitalization,
recovery) of these outpatients who were followed up by
telephone or personal visits were evaluated retrospectively.
The treatment was decided by the filiation teams according
to the age and comorbid status of the outpatients.
Patients were divided into three groups according to the
treatment they received such as hydroxychloroquine,
favipiravir and both hydroxychloroquine + favipiravir.
The primary outcomes were symptom improvement,
PCR negativity and need for hospitalization. The effects of
hydroxychloroquine and favipiravir on the clinical course
were evaluated statistically.
2

Statistical calculations were performed using SPSS
(Statistical Package for the Social Science; IBM Corp,
Armonk, NY, USA), version 26. Categorical variables
between groups were compared with the chi-square test
and confidence interval. ANOVA F test or student-t test
was used for the analysis of continuous variables, where
appropriate. Logistic regression analysis was performed to
explore which factors were predictive for clinical course.
Significant variables at p < 0.05 in univariate analyses were
introduced in the initial multivariate model. A stepwise
approach was applied to evaluate the iteration of variables
and to control potential confounders. A p value less than
0.05 was considered statistically significant.
3. Results
3.1. Demographic findings
During the study period, a total of 1957 outpatients test
results were positive for SARS-CoV-2 RNA. Of these
outpatients, 468 of them were excluded from the study
due to being under 18 years of age, previous COVID-19
diagnosis, pregnancy, and missing data. Finally, we
enrolled 1489 outpatients in this study. Overall, 775 (52%)
patients were male and the mean age of patients was
38.9 ± 11.1 years. The minority of the patients (11.6%)
had at least one comorbid disease including diabetes
(10.1%), hypertension (3.2%), and malignancy (0.6%).
The proportion of asymptomatic patients was 720 (48.4%),
while the number of patients with upper respiratory tract
infection was 644 (43.3%), and the number of patients
with lower respiratory tract infection was 230 (15.4%).
Demographic and laboratory findings are presented in
Table 1.
Of these patients, 537 of them received favipiravir,
545 of them received hydroxychloroquine, and 407 of
them received both favipiravir and hydroxychloroquine.
At least one side-effect attributed to the favipiravir and/
or hydroxychloroquine was observed in 17.5% of patients.
The side-effects of antiviral treatment were gastrointestinal
disturbances (12.1%), allergic reactions (3.5%), and
cardiac arrhythmia (1%). No significant difference was
observed between patients receiving favipiravir and
hydroxychloroquine in terms of side effects (p = 0.086).
3.2. Effects of antivirals on symptom improvement
The rates of symptoms were similar in symptomatic
patients except for the loss of smell and taste on the first
day of treatment (Table 1). Cough was less common in
the group of patients who received hydroxychloroquine
on the 3rd day of treatment (p = 0.029). In addition, the
group that received hydroxychloroquine had a higher rate
of recovery from joint pain on the 14th day and myalgia
on the 30th day (p = 0.001 and p = 0.046). The number

T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Platformu (2020). Website https://covid19.saglik.gov.tr [Accessed 15.12.2020]
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Table 1. Demographic, laboratory, and follow-up findings of COVID-19 outpatients.
Favipiravir
Total
Favipiravir
+hydroxychloroquine
(n = 1489. 100%) (n = 537. 36.1%)
(n = 407, 27.3%)

Hydroxychloroquine
P value
(n = 545. 36.6%)

Male (n. %)

775 (52)

278 (51.8)

210(51.6)

287 (52.7)

0.941

Age (years) (Mean ± SS /
Median min-max)

38.9 ± 11.1
39 (16–82)

39.7 ± 11.2
40 (18–82)

39 ± 10.8
39 (18–77)

37.9 ± 11.1
37 (16–80)

0.021

At least one underlying disease

172 (11.6)

58 (10.8)

51(12.5)

63 (11.6)

0.723

Diabetes mellitus

150 (10.1)

51 (9.5)

46 (11.3)

53 (9.7)

0.617

Hypertension

48 (3.2)

12 (2.2)

16 (3.9)

19 (3.5)

0.293

Malignancy

9 (0.6)

1 (0.2)

1 (0.7)

5 (0.9)

0.324

Comorbidity (n, %)

Symptoms at the time of diagnosis (n. %).
Asymptomatic patients

720 (48.4)

269 (50.1)

187 (45.9)

264 (48.4)

0.449

Patients with upper respiratory
symptoms

644(43.3)

208(38.7)

195 (47.9)

241(44.2)

0.016

Patients with pneumonia

230 (15.4)

108 (20.1)

53 (13)

69 (12.7)

0.001

Fever

173 (11.6)

56 (10.4)

49 (12)

68 (12.1)

0.551

Cough

253 (17)

99 (18.4)

76 (18.7)

78 (14.3)

0.111

Sore throat

176 (11.2)

62 (11.5)

48 (11.8)

57 (10.5)

0.767

Shortness of breath

89 (6)

24 (4.5)

25 (6.1)

40 (7.3)

0.136

Myalgia

271 (18.2)

106 (19.7)

75 (18.4)

90 (16.5)

0.384

Joint pain

14 (0.9)

0

0

14 (2.6)

-

Loss of smell and taste

157 (10.5)

49(9.1)

58 (14.3)

50 (9.2)

0.017

Diarrhea

66 (4.4)

23 (4.3)

18 (4.4)

25 (4.6)

0.987

Laboratory findings at the time of diagnosis (Mean ± SS / Median min-max)
White blood cell (cells/mm3)

5.8 ± 1.4
5.6 (1.6–15.2)

5.6 ± 1.4
5.6 (1.6–15.2)

5.8 ± 1.4
5.7 (3.1–12.6)

5.8 ± 1.5
5.6 (2.3–13.3)

0.078

Lymphocyte (cells/mm3)

2.2 ± 4
1.6 (0.3–47.8)

1.9 ± 2.5
1.6 (0.3–30.3)

2.2 ± 4
1.5 (0.5–41.7)

2.5 ± 5
1.7 (0.5–47.8)

0.075

Neutrophil (cells/mm3)

4.2 ± 7
3.3 (0.4–85.7)

4.2 ± 7.9
3.2 (0.6–85.7)

4.5 ± 7.3
3.4 (0.8–65.1)

4 ± 5.7
3.3 (0.4–72)

0.587

Glucose (mg/dL)

102 ± 32
96 (52–510)

104 ± 36
98 (61–510)

100 ± 28
96 (72–297)

100 ± 28
96 (52–395)

0.234

AST (U/L)

28.8 ± 21.8
23 (4–268)

29 ± 24.8
23 (5–268)

26 ± 15
22 (4–111)

30.7 ± 23
25 (8–268)

0.024

ALT (U/L)

28 ± 14.8
25 (9-214)

28 ± 16.2
24 (9-161)

26 ± 10.4
24 (11-74)

29.5 ± 16
26 (12-214)

0.010

LDH (U/L)

206 ± 68.3
199 (18-447)

211 ± 69
202 (20-429)

203 ± 65.1
195 (25-447)

202 ± 69
200 (18-374)

0.535

BUN (mg/dL)

26 ± 9.5
25.5 (2-65)

26 ± 9.5
26 (8-65)

25 ± 8.8
25 (2-55)

26.8 ± 10
26 (4-58)

0.172

Serum creatinine (mg/dL)

0.9 ± 0.19
0.9 (0.1–2.19)

0.9 ± 0.19
0.9 (0.1–2.19)

0.9 ± 0.17
0.9 (0.1–1.7)

0.9 ± 0.19
0.9 (0.1–1.7)

0.570
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Table 1. (Continued).
D-dimer (ng/mL)

295 ± 488.6
190 (1–9060)

310 ± 576
204 (1–9060)

304 ± 444
191 (3–444)

271 ± 393
164 (1–4130)

0.871

Ferritin (ng/mL)

84 ± 120.5
39.4 (3–1235)

85 ± 116
37 (3–890)

76 ± 91
36.9 (3–502)

88 ± 144
44.4 (5–1235)

0.606

Procalcitonin (ng/mL)

0.06 ± 0.1
0.03 (0.01–1.1)

0.06 ± 0.08
0.04 (0.01–0.5)

0.04 ± 0.03
0.03 (0.01–0.1)

0.08 ± 0.2
0.03 (0.01–1.1)

0.241

CRP (mg/dL)

8.8 ± 15.8
3.7 (0.5–156)

9.2 ± 17
4.1 (0.5–156)

9.7 ± 18.5
3.7 (0.1–135)

7.6 ± 11.8
3.3 (0.1–90)

0.085

At least one symptom

605 (40.6)

221 (41.2)

169 (41.5)

215 (39.4)

0.778

Fever

78 (5.2)

33 (6.1)

18 (4.4)

27 (5)

0.470

Cough

220 (14.8)

90 (16.8)

67 (16.5)

63 (11.6)

0.029

Sore throat

103 (6.9)

45 (8.4)

23 (5.7)

35 (6.4)

0.225

Shortness of breath

74 (5)

21 (3.9)

22 (5.4)

31 (5.7)

0.369

Myalgia

179 (12)

70 (13)

51 (12.5)

58 (10.6)

0.444

Joint pain

10 (0.7)

1 (0.2)

0

9 (1.7)

Loss of smell and taste

169 (11.3)

57 (10.6)

44 (10.8)

68 (12.5)

0.582

Diarrhea

43 (2.9)

14 (2.6)

9 (2.2)

20 (3.7)

0.385

PCR positivity

(1213)
454 (37.4)

(432)
169 (39.1)

(322)
139 (43.2)

(459)
146(31.8)

0.004

At least one symptom

442 (29.7)

160 (29.8)

124 (30.5)

158 (29)

0.884

Fever

49 (3.2)

21 (3.9)

6 (1.5)

22 (4)

0.056

Cough

183 (12.3)

72 (13.4)

55 (13.5)

56 (10.3)

0.204

Sore throat

74 (5)

30 (5.6)

12 (2.9)

32 (5.9)

0.088

Shortness of breath

58 (3.9)

20 (3.7)

21(5.2)

17 (3.1)

0.267

Myalgia

137 (9.2)

54 (10.1)

41(10.1)

42 (7.7)

0.321

Joint pain

0

0

0

0

Loss of smell and taste

116 (7.8)

40 (7.4)

33 (8.1)

43 (7.9)

0.925

Diarrhea

26 (1.7)

11 (2)

4 (1)

11 (2)

0.404

At least one symptom

239 (16.1)

105 (19.6)

68 (16.7)

66(12.1)

0.003

Fever

25 (1.7)

10 (1.9)

7 (1.7)

8 (1.5)

0.876

Cough

91 (6.1)

44 (8.2)

23 (5.7)

24 (4.4)

0.031

Sore throat

33 (2.2)

18 (3.4)

6 (1.5)

9 (1.7)

0.083

Shortness of breath

30 (2)

13 (2.4)

10 (2.5)

7 (1.3)

0.333

Myalgia

63 (4.2)

31 (5.8)

15 (3.7)

17 (3.1)

0.076

Joint pain

34 (2.3)

23 (4.3)

6 (1.5)

5 (0.9)

0.001

Loss of smell and taste

59 (4)

24 (4.5)

17(4.2)

18 (3.3)

0.599

Diarrhea

8 (0.5)

4 (0.7)

2 (0.5)

2 (0.4)

0.684

PCR positivity

(1105)
35 (3.2)

(389)
9 (2.3)

(298)
11 (3.7)

(418)
15 (3.6)

0.502

3th day of follow-up

5th day of follow-up

14th day of follow-up
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Table 1. (Continued).
30th day of follow-up
At least one symptom

180 (12.1)

70 (13)

61 (15)

49 (9)

0.014

Fever

26 (1.7)

12 (2.2)

10 (2.5)

4 (0.7)

0.059

Cough

56 (3.8)

21 (3.9)

21 (5.2)

14 (2.6)

0.115

Sore throat

22 (1.5)

8 (1.5)

7 (1.7)

7 (1.3)

0.830

Shortness of breath

26 (1.7)

9 (1.7)

11 (2.7)

6 (1.1)

0.180

Myalgia

57 (3.8)

29 (5.4)

14 (3.4)

14 (2.6)

0.046

Joint pain

37 (2.5)

12 (2.2)

11 (2.7)

14 (2.6)

0.913

Loss of smell and taste

38 (2.6)

15 (2.8)

15 (3.7)

8 (1.5)

0.088

Diarrhea

4 (0.3)

1 (0.2)

2 (0.5)

1 (0.2)

0.685

*BUN: Blood urea nitrogen, AST: Aspartateaminotransferase, ALT: Alanine aminotransferase, LDH: Lactate dehydrogenase, CRP:
C-reactive protein, PCR: Polymerase chain reaction.

of patients whose all symptoms improved on the 14th day
of follow-up was higher in the group of patients receiving
hydroxychloroquine (p = 0.003).
Logistic regression model was used to examine the
independent effects of antivirals on symptom improvement.
The antiviral drugs, the presence of comorbidity, and
pneumonia are included in this model. On the 14th day
of follow-up, regardless of the presence of comorbidity
and pneumonia, symptom improvement was 1.8 times
higher among patients who received hydroxychloroquine
compared to patients who received favipiravir (Table 2).
3.3. Effects of antivirals on PCR negativity
On the 3rd day of follow-up, PCR negativity rate was higher
in patients receiving hydroxychloroquine (p = 0.004), but
this difference was not significant on the 14th day (p =
0.502). The presence of pneumonia as a confounding factor
was included in the logistic regression model to examine
the independent effects of antivirals on PCR negativity at
3rd day of follow-up. Sex, age, and comorbidity were not
included in this analysis because they were not found to
be related with PCR negativity. Accordingly, on the 3rd
day of the treatment, it was found that PCR negativity was
higher in the asymptomatic patients (Odds ratio [OR]:
1.41, 95% Confidence Interval [CI]: 1.12-1.79), in patients
without pneumonia (OR: 1.57, 95% CI: 1.11-2.24) and
in patients who received hydroxychloroquine compared
to patients received favipiravir (OR: 1.44, 95% CI: 1.09–
1.91). Combined antiviral therapy had no effect on PCR
negativity on the 3rd day of treatment (Table 3).
3.4. Subgroup analysis of hospitalized patients
All patients included in the study recovered from
COVID-19 during the follow-up period. A total of
40 patients were hospitalized; 7 of them had severe
pneumonia, 5 of them were followed in Intensive Care
Unit (ICU), and only one patient required mechanical

ventilation. Hospitalization rates were similar in patients
receiving favipiravir and hydroxychloroquine (p = 0.144)
(Table 1).
Logistic regression analysis was used for evaluating
independent factors affecting hospitalization. The presence
of pneumonia was included in the model as an effect
modifier. The odds ratio for age indicated that each 1 -year
increase in age increased the relative risk of hospitalization
by 1.04-fold (Table 4). In the presence of pneumonia
at the time of diagnosis, the hospitalization rate was 6.6
times higher in patients who received favipiravir than
those who received hydroxychloroquine. In similar, the
hospitalization rate was 7.3 times higher in patients who
received combined therapy compared with those who
received hydroxychloroquine (Table 4).
4. Discussion
Aside from the now, more than 1.8 million Turkish people
have been infected with SARS-Cov-2 according to the
Republic of Turkey Ministry report**. Although social
distancing, staying at home and wearing face masks served
to reduce the hospital burdens and spread them over time,
these measures only reduced reproduction numbers to
about 1.0 [2]. Moreover, considering that isolation policies
will be lifted over time, it can be predicted that many
people will be exposed to the COVID-19 in the future,
even if these social isolation measures are maintained.
While the vast majority of COVID-19 patients is at
low risk of progression or show the infection without
symptoms, for the remaining patients, outpatient treatment
is necessary for preventing hospitalization and disease
progression. Thus, the way to prevent loss of life and return
the society with normal functioning is an effective and safe
outpatient treatment [3].
Although there is no anti-viral treatment with
proven efficacy in the treatment of COVID-19, drugs
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Table 2. Factors Affecting Symptom improvement in symptomatic outpatients on the 14th day of
follow-up (n = 877)
Risk factors

ORadj (95% confidence interval)

p value

Absence of comorbidity

1.9 (1.0–3.5)

0.054

Absence of pneumonia

1.4 (0.9–2.1)

0.145

Hydroxychloroquine

1.8 (1.2–2.7)

0.005

Hydroxychloroquine + Favipiravir

1.1 (0.7–1.7)

0.622

Favipiravir (Ref)

1

Antiviral treatment

Table 3. Factors Affecting PCR negativity on the 3th day of follow-up (n = 1489).
Risk factors

ORadj (95% confidence interval)

p value

Lack of symptoms

1.41 (1.12–1.79)

0.004

Absence of pneumonia

1.57 (1.11–2.24)

0.012

Hydroxychloroquine

1.44 (1.09–1.91)

0.010

Hydroxychloroquine + Favipiravir

0.89 (0.66–1.19)

1.424

Favipiravir (Ref)

1

Antiviral treatment

Table 4. Factors affecting hospitalization of COVID-19 outpatients (n = 1489).
Risk factors

ORadj (95% confidence interval)

P value

Age (years)

1.04 (1.01–1.07)

0.018

Presence of comorbidity

1.4 (0.6–3.2)

0.436

Presence of any symptoms

4.6 (2.0–10.7)

<0.001

Favipiravir

0.8 (0.3–2.2)

0.669

Hydroxychloroquine + Favipiravir

0.7 (0.3–2.2)

0.565

Hydroxychloroquine

Ref

Antiviral treatment

Antiviral treatment in outpatients with pneumonia
Favipiravir

6.6 (2.4–18.4)

<0.001

Hydroxychloroquine + Favipiravir

7.3 (2.0–26.9)

0.003

Hydroxychloroquine

Ref

such as chloroquine/hydroxychloroquine, azithromycin,
lopinavir/ritonavir, favipiravir and remdesivir have been
used widely. Hydroxychloroquine and favipiravir, which
are included in the treatment protocol in many national
treatment guidelines, are also used in our country
according to The Republic of Turkey Ministry of Health
COVID-19 guideline**. There are many studies about
these drugs in the literature especially on hospitalized
patient groups [4–7]. Early outpatient disease is not the
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same as a later hospitalization illness, as a result, different
treatments’ affects may be obtained in different patient
groups [3]. Due to the limited number of studies with
large numbers of outpatients examining early initiation of
antiviral therapy, we examined the effects of these drugs,
which were initiated in early period, on the clinical course
of outpatients.
Chloroquine and its derivatives are widely used as
immunomodulators in the treatment of rheumatic diseases
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[8]. As the pharmacological property of chloroquine and
its derivatives are studied, additional clinical applications,
especially based on its antiviral activity against human
coronaviruses are increasingly appreciated [9]. The action
of hydroxychloroquine such as antioxidant activities and
regulation in proinflammatory cytokines encourages its
administration due to the cytokine storm in patients with
severe COVID-19 [10]. Therefore, hydroxychloroquine
has been used in the treatment with the assumption that
it will be a protective agent in SARS-CoV-2 infection with
its antiviral and autoimmune regulating effect. While
hydroxychloroquine has been found to be effective in
the prophylaxis and treatment of COVID-19 in some
studies, other studies have claimed otherwise [7,11,12].
In a meta-analysis conducted by Elavarasi et al., there was
no significant difference in virologic clearance between
placebo and hydroxychloroquine in the meta-analysis
of two randomized-controlled trials and three cohort
studies [11]. In addition, the time of fever remission,
clinical deterioration, development of ARDS and need
for mechanical ventilation rates were similar between
the hydroxychloroquine arm and standard of care [11].
In a meta-analysis in which four randomized controlled
trials were analyzed, the use of hydroxychloroquine for
COVID-19 prophylaxis, compared to placebo, did not
reduce the risks of developing COVID-19, hospitalization
or mortality; however, hydroxychloroquine use
increased the risk of adverse events [12]. In our study,
hydroxychloroquine was found effective in improving
symptoms. We also showed COVID-19 outpatients who
received hydroxychloroquine had higher rate of PCR
negativity on the 3rd day, but no significance was found
in terms of PCR negativity on the 14th day. In addition,
the use of hydroxychloroquine was associated with fewer
hospitalization rates in COVID-19 outpatients with
pneumonia. Our results may be due to the higher rate of
asymptomatic or mildly symptomatic patients in the group
receiving hydroxychloroquine. Eventually, the fact that the
patient groups were not randomly selected prospectively
and the absence of a control group make the generalizability
of our research findings debatable. In addition, subgroups
of patients treated with hydroxychloroquine and/or
favipiravir did not have similar disease severities in our
study. The higher rate of pneumonia at the time of diagnosis
in patients receiving favipiravir may explain the higher rate
of hospitalization in this patient group. Therefore, further
studies with homogeneous patient groups to be arranged
prospectively are needed.
Favipiravir, a potent inhibitor of RNA-dependent
RNA polymerase, was approved for reemerging pandemic
influenza in Japan [13]. Favipiravir has shown in vitro
activity against SARS-CoV-2 by reduction in the number
of infectious particles and cytopathic effect [14]. There

are mostly observational studies evaluating the efficacy
of favipiravir in different patient groups, and conflicting
results have been obtained in these studies [15,16]. Two
randomized, open-label controlled trials are currently
underway to evaluate the efficacy of early favipiravir
treatment in outpatients with early stage COVID-19
[17,18]. In our study, the parameters used to evaluate
clinical course, were yielded more positive outcomes
in patients receiving hydroxychloroquine compared to
patients receiving favipiravir. The positive effects of early
antiviral therapy on the clinical course may be attributed
to the anti-inflammatory and immunomodulatory effects
rather than the antiviral effect. A possible explanation for
the superiority of favipiravir over combination therapy in
our study can be attributed to the fact that the number
of asymptomatic patients in the patient group receiving
favipiravir is higher compared to the patient group
receiving combination therapy.
Our study has some limitations. The first of these was
the absence of a control group that did not receive antiviral
treatment. Secondly, since we did not have complete access
to the entire number of patients diagnosed during the study
period, it is difficult to assess whether our findings were
representative of the entire population. Similarly, we could
not access any information about the quality control of the
data. Another limitation of the study was that the different
subgroups of patients treated with different medications
had different disease severities, and that it is difficult to
make comparisons of the effectiveness of these drugs. In
addition; observational, retrospective and nonrandomized
design of our study restricted the reliability of our findings,
even though large number of patients and multicentric
design.
The antiviral drugs administered in the early phase
of infection can shorten the course of the clinical disease
and thus may reduce the infectiousness by reducing
viral spread. Data of the ongoing randomized controlled
trials and meta-analyses will indicate the efficacy of these
antivirals in COVID-19 outpatient clearly, so we need to
wait for more clinically valid evidence to confirm the value
of this antiviral agent for COVID-19 treatment.
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